GE HealthCare Technologies Inc. (GEHC)
GEHC Launches MIM ComboTherapy for GYN Cancer Radiation Planning
GE HealthCare launches MIM ComboTherapy to improve radiation planning for gynecologic cancers with advanced dose visualization.
GE HealthCare Just Crashed 13% on a Guidance Cut. Here's the Case for Buying the Dip
GE HealthCare (NASDAQ: GEHC | GEHC Price Prediction) currently trades at $59.49, well below the Wall Street consensus price target of $89.74.
GE HealthCare Q1 2026: Inflation And Execution Risks Weigh On Outlook
GE HealthCare Technologies is rated a hold following 1Q26, reflecting resilient demand but significant near-term margin pressure. GEHC maintains a robust $21.8B backlog and credible innovation pipeline, supporting mid-single-digit revenue growth, yet faces execution risk from lagged pricing actions. Profitability was hit by $250M in inflation headwinds, tariffs, and Patient Care Solutions weakness, leading to a downward revision in adjusted EPS guidance to $4.80–$5.00.
GE HealthCare: Soft Execution More Than Priced Accordingly
GE HealthCare shares have fallen to $60 after a soft Q1 and guidance cut, now trading at the low end of their post-spin range. Q1 organic growth was 2.9%, below full-year targets, and EBIT margin guidance was trimmed, but valuation multiples have compressed to 12–13x earnings. Despite headwinds—tariffs, supplier issues, and rising costs—GE HealthCare maintains 3–4% organic growth guidance and is integrating the Intelerad acquisition for incremental EBITDA.
GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript
GE HealthCare Technologies Inc. (GEHC) Q1 2026 Earnings Call Transcript
GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin Declines
GE HealthCare misses Q1 EPS but tops revenue estimates as Imaging, AVS and PDx growth offset PCS weakness; shares slide due to margin pressure.
GE HealthCare shares tumble after profit miss and guidance cut
GE Healthcare Technologies Inc (NASDAQ:GEHC) shares fell sharply on Wednesday after the medical imaging company reported first-quarter earnings that missed Wall Street expectations and trimmed its full-year profit and margin outlook, citing supply chain pressures and elevated costs. Shares were down approximately 12.8% in morning trading.
GE HealthCare Technologies (GEHC) Lags Q1 Earnings Estimates
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $0.99 per share, missing the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.01 per share a year ago.
GEHC Moves Manganese-Based MRI Contrast Agent Into Phase 2/3 Trial
GE HealthCare doses first patient in Phase 2/3 LUMINA trial for mangaciclanol, a manganese MRI contrast agent with FDA Fast Track status.
GE HealthCare to Post Q1 Earnings: What's in Store for the Stock?
GEHC heads into Q1 earnings with steady demand and a $21.8B backlog, but China weakness and tariff costs may weigh on growth and margins.
Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Earnings Growth & Price Strength Make GE HealthCare Technologies (GEHC) a Stock to Watch
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
